Streetbeat News

Stock Prices

AEZS

Aeterna Zentaris Inc. has announced a name change to COSCIENS Biopharma Inc. The company's shares will begin trading under the new symbol 'CSCI' on NASDAQ and TSX starting August 9, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:10 pm

AIRG

Airgain expects Q3 sales to be between $15.25M and $16.75M, with an estimated midpoint of $16.2M. The company also anticipates an adjusted net loss per share of $(0.01) at the midpoint, better than the estimated $(0.04).

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:09 pm

SHOP

Shopify Inc (NYSE:SHOP) is set to report its Q2 earnings, with JPMorgan analysts highlighting key factors such as growth sustainability and cost management. Despite a recent share price drop, JPMorgan rates Shopify as Overweight with a $74 price target by December 2025, suggesting a 42% upside. Risks include macroeconomic challenges and slower growth in GMV/GPV.

Portfolio Pulse from Henry Khederian

August 06, 2024 | 10:06 pm

MBI

MBIA (NYSE:MBI) reported a significant quarterly loss of $(2.90) per share, missing the analyst consensus estimate of $(0.30) by a wide margin. This represents a 544.44% increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:06 pm

PRCH

Porch Group has revised its FY24 revenue outlook from $230M-$240M to $190M-$200M and its adjusted EBITDA outlook from $2.5M-$12.5M to $(20)M-$(10)M.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:04 pm

PRCH

Porch Group has reaffirmed its revenue expectations for FY24, projecting between $450 million and $470 million, aligning closely with the estimated $457.544 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:01 pm

TMCI

Treace Medical Concepts (NASDAQ:TMCI) reported Q2 2024 GAAP EPS of $(0.34), missing the $(0.29) estimate, but sales of $44.455M beat the $43.000M estimate. EPS decreased by 70% YoY, while sales increased by 5.96% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:00 pm

RPD

Rapid7 has provided its Q3 and FY24 financial guidance. For Q3, the company expects adjusted EPS between $0.50 and $0.53, slightly below the $0.53 estimate, and revenue between $209M and $211M, in line with the $209.24M estimate. For FY24, Rapid7 anticipates adjusted EPS between $2.15 and $2.20, close to the $2.17 estimate, and revenue between $833M and $837M, aligning with the $833.58M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 10:00 pm

AQST

Aquestive Therapeutics has projected its FY24 revenue to be between $57 million and $60 million, surpassing the estimated $49.792 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:59 pm

OR

Osisko Gold Royalties reported Q2 2024 adjusted EPS of C$0.18, beating the estimate of C$0.16. However, sales were C$64.846 million, missing the estimate of C$67.981 million.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 9:59 pm